We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.19 | 0.75% | 25.45 | 25.54 | 25.20 | 25.33 | 46,479,621 | 00:58:17 |
By Ian Walker
GlaxoSmithKline PLC's (GSK.LN) joint-venture company ViiV Healthcare said Thursday that a global phase 3 "Atlas-2M" study of rilpivirine for the treatment of HIV met its primary endpoint.
ViiV Healthcare--which is jointly owned by Pfizer Inc. (PFE)--said the study showed a combination of cabotegravir and rilpivirine administered every eight weeks is similar to a four-week administration.
"The Atlas-2M study results mean that people living with HIV could maintain viral suppression with six total treatments per year, instead of a daily oral treatment 365 times per year," Viiv Healthcare's Head of Research & Development Kimberly Smith said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 22, 2019 02:55 ET (06:55 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions